NCT07114614 Fatty Acid Binding Proteins and Markers of Cellular Senescence in Cancer Survivors
| NCT ID | NCT07114614 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Case Comprehensive Cancer Center |
| Condition | Marker; Structural |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-09 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2026-09 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to investigate whether cancer survivors have higher levels of proteins called Fatty Acid Binding Proteins as well as 12 different markers of cellular senescence than people who have never had cancer. Investigators believe that these levels may be elevated in cancer survivors as a result of their cancer and the treatments they received and may put them at higher risk for chronic conditions such as high cholesterol, diabetes, high blood pressure, and obesity. This study will also compare the levels of these proteins and inflammatory markers in the blood with different aspects of cancer treatment the survivors received. Investigators are investigating if there is a correlation between levels of these proteins and markers, the type of treatment cancer survivors received, and development of metabolic conditions.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of at least one malignancy for which chemotherapy, radiation, and/or stem cell transplantation was utilized as part of treatment * Completed all therapeutic interventions for their malignancy and are at least 2 years off therapy * At least 1-year post-stem cell transplant for malignant condition Exclusion Criteria: 1. Pregnancy at the time of the study 2. Any autoimmune condition including but not limited to lupus, rheumatoid arthritis, Crohn's disease, ulcerative colitis, type 1 diabetes, EXCEPT well-controlled autoimmune hypothyroidism for at least 6 months 3. Presence of active graft versus host disease 4. Malignancy treated using surgery only 5. Acute relapsed disease or second malignancy 6. Transplant for non-malignant conditions (e.g. cell disease, Hurler syndrome) 7. Currently taking systemic steroids and/or immunosuppressant medications 8. Acute illness necessitating hospitalization in the 30 days prior to blood draw 9. Presence of a chronic inflammatory disease EXCEPT obesity 10. Fever, active infection or inflammation, or taking antibiotics at the time of blood draw 11. A diagnosis of Type 2 diabetes or Hypertension treated with medication 12. Currently lipid lowering medications 13. Growth hormone deficiency or hypothalamic dysfunction
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07114614 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 50 Years, studying Marker; Structural. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07114614 currently recruiting?
Yes, NCT07114614 is actively recruiting participants. Contact the research team at Lisa.hackney@uhhospitals.org for enrollment information.
Where is the NCT07114614 trial being conducted?
This trial is being conducted at Cleveland, United States.
Who is sponsoring the NCT07114614 clinical trial?
NCT07114614 is sponsored by Case Comprehensive Cancer Center. The trial plans to enroll 120 participants.